| BASF–Kaiima: plant biotechnology, 201707– collab research multi-year using EP technology to discover herbicide resistent traits |
2017-07-17 |
| Maruho–4SC: Kv1.3 inhibitors, 201707–202009 license ww excl for up to total €208m upfront + milestones plus royalties TERMINATED 9/20 |
2017-07-15 |
| Diagenode–PreOmics: proteomic sample preparation, –201707 collab developm combi of Bioruptor + iST Kit to clean peptides for MS |
2017-07-14 |
| NofaGroup–Cotecna: investment, 201707 acquisition of NofaGroup by Cotecna Inspection SA |
2017-07-13 |
| ABF–Genedata: bioinformatics, 201707– supply expansion use of Genedata Selector by AB Enzymes for decision support |
2017-07-11 |
| Blueprint Genetics–Creathor Ventures: investment, 201707 financing round totalling up to €14m incl new + co-lead investor Creathor Venture |
2017-07-11 |
| Blueprint Genetics–Inventure: investment, 201707 financing round totalling up to €14m incl existing + co-investor Inventure |
2017-07-11 |
| Blueprint Genetics–MedTech Innovation Partners: investment, 201707 financing round totalling up to €14m incl new + co-lead investor MTIP |
2017-07-11 |
| Blueprint Genetics–Pontos Group: investment, 201707 financing round totalling up to €14m incl existing + co-investor Pontos Group |
2017-07-11 |
| Blueprint Genetics–SEVERAL: investment, 201707 financing round up to €14m led by Creathor Venture + MTIP + incl Inventure + Pontos Group |
2017-07-11 |
| Nestlé–Enterome: diagnostics, 201707– collab establishm of 50/50 jv MDP to develop microbiome-based diagnostics except for immuno-oncology |
2017-07-11 |
| CRISPR Therapeutics–Neon Therapeutics: T cell therapy, 201707– collab combi of proprietary technologies to develop T cell therapies |
2017-07-10 |
| Endress+Hauser–GUS Group: investment, 201707 acquisition of AJ Blomesystem GmbH by GUS Group |
2017-07-01 |
| Evotec–Hamburg (govt): grant, 201707– 201906 RnD grant from IFB Hamburg to develop AB-based cancer therapies with UKE |
2017-07-01 |
| Global Bioenergies–SEVERAL: investment, 201706 capital increase €10.24m via private placement of 640k new shares at €16/share |
2017-06-30 |
| mySugr–Roche: investment, 201706 acquisition of remaining shares by Roche |
2017-06-30 |
| Evotec–Censo Biotechnologies: stem cell technology, 201706–201905 strategic collab €na with Censo supplying iPS cell lines to Evotec |
2017-06-28 |
| Indi Molecular–Merck (DE): investment, 201706 financing round Series A totalling $11.5m led by Merck Ventures + Legend Capital |
2017-06-28 |
| Indi Molecular–SEVERAL: investment, 201706 financing round Series A $11.5m led by Merck Ventures + Legend Capital |
2017-06-28 |
| BioGeneration Ventures–EU (govt): investment, 201706 investment by EIF + other new investors bringing total capital of BGV III to €66m |
2017-06-27 |
| BioGeneration Ventures–SEVERAL: investment, 201706 investm by EIF + other new investors bringing total capital of BGV III to €66m with max target €75m |
2017-06-27 |
| Catalym–BioGeneration Ventures: investment, 201706 CatalYm GmbH is existent investment of BGV III fund |
2017-06-27 |
| Sensovation–Miltenyi Biotec: investment, 201706 acquisition by Milteny from HeidelbergCapital + KfW/tbg |
2017-06-27 |
| Takeda–JSR Corp: cell line development, 201706– commercial license to use Selexis’ SUREtechnology for developm of fusion proteins |
2017-06-27 |
| Ottobock–EQT: investment, 201706 EQT VII fund to acquire 20% stake from Otto Bock HealthCare GmbH valuing Ottobock at €3.15b |
2017-06-24 |
| DiaSorin–Qiagen: in vitro diagnostics, 201706– collab to adopt select Qiagen assays for use on Liaison platform |
2017-06-22 |
| Repare Therapeutics–SEVERAL: investment, 201706 financing round Series A $68m co-led by Versant Ventures + MPM Capital |
2017-06-22 |
| AlsaChim–Shimadzu: investment, 201706 acquisition €na of 100% of AlsaChim by Shimadzu Europe |
2017-06-21 |
| FB Health–Invent Farma/Neuraxpharm: investment, 201706 acquisition €na of FB Health by Invent Farma/Neuraxpharm (formed 8/16 by Apax Partners) |
2017-06-21 |
| Debiopharm–Almac: kinase inhibitor, 201706– license ww excl to Wee-1 kinase inhibitor programme of Almac Discovery |
2017-06-20 |
| Facio Therapies–Evotec: investment, 201706c financing round totalling €4.8m incl strategic investment by Evotec |
2017-06-20 |
| Facio Therapies–SEVERAL: investment, 201706c financing round €4.8m incl Evotec + members of intl FSHD community |
2017-06-20 |
| Idorsia–JnJ: investment, 201706 acquisition of 9.9% share in Idorsia by Cilag Holding AG via conversion of CFH135.4m convertable loan |
2017-06-20 |
| Euroimmun–PerkinElmer: investment, 201706–201712 acquisition $1.3b in cash |
2017-06-19 |
| Hopp Group–CRS Clinical Research Services: investment, 201706 management buy-out of CRS from LTS via holding Apleonex AG |
2017-06-19 |
| Takeda–Wilex: antibody-drug conjugates, 201706– collab developm of ADCs using ATACs for up to 3 targets Heidelberg Pharma + Millennium |
2017-06-19 |
| TxCell–Miltenyi Biotec: lentiviral vector, 201706– supply of lentiviral vector for TxCell’s CAR-Tregs targeting transplant rejection by Lentigen |
2017-06-19 |
| Broughton Laboratories–Thermo Fisher: LC system, 201706 supply two Vanquish Flex UPLC systems coupled to TSQ Endura TQ-MS detectors |
2017-06-16 |
| Broughton Laboratories–Thermo Fisher: mass spectrometer, 201706 supply two Vanquish Flex UPLC systems coupled to TSQ Endura TQ-MS detectors |
2017-06-16 |
| GreenBone–Helsinn: investment, 201706 2nd financing round incl €2m from lead investor Helsinn Investment Fund |
2017-06-16 |
| GreenBone–SEVERAL: investment, 201706 2nd financing round incl lead investor Helsinn Investment Fund |
2017-06-16 |
| Idorsia–OTHER: investment, 201706 listing at SIX Swiss Exchange as part of acquisition of Actelion by JnJ and spin-off of Idorsia |
2017-06-16 |
| Medicxi Ventures–Alphabet: investment, 201706 closing totalling $300m of MG1 fund incl cornerstone investors EIF + Novartis + Verily |
2017-06-15 |
| Medicxi Ventures–EU (govt): investment, 201706 closing totalling $300m of MG1 fund incl cornerstone investors EIF + Novartis + Verily |
2017-06-15 |
| Medicxi Ventures–Novartis: investment, 201706 closing totalling $300m of MG1 fund incl cornerstone investors EIF + Novartis + Verily |
2017-06-15 |
| Medicxi Ventures–SEVERAL: investment, 201706 closing $300m of MG1 fund incl cornerstone investors EIF + Novartis + Verily |
2017-06-15 |
| TissUse–Minapharm: organ-on-a-chip technology, 201706– license for HuALN platform for Multi-Organ-Chip applications from ProBioGen |
2017-06-15 |
| Bayer–China (govt): wheat breeding, 201706– collab 2y with SIBS + SIPPE to improve wheat yields via improved photosynthetic efficiency |
2017-06-14 |
| Pfizer–Basilea: isavuconazole, 201706– license CHF70m upfront + $427m milestones + royalties for prod + sales in Europe + RU + TR + IL |
2017-06-14 |
| Selexis–JSR Corp: investment, 201706 acquisition €na of Selexis SA by JSR Life Sciences |
2017-06-14 |
| Centogene–Careventures: investment, 201706 financing round Series A totalling €25m incl co-investor Careventures |
2017-06-13 |
| Centogene–Crédit Mutuel-CIC: investment, 201706 financing round Series A totalling €25m incl co-investor CIC Capital |
2017-06-13 |
| Centogene–DPE Deutsche Private Equity: investment, 201706 financing round Series A totalling €25m incl co-investor DPE |
2017-06-13 |
| Centogene–SEVERAL: investment, 201706 financing round Series A €25m led by TVM Capital + incl DPE + Careventures + CIC Capital |
2017-06-13 |
| Centogene–TVM: investment, 201706 financing round Series A totalling €25m incl lead investor TVM Capital Life Science |
2017-06-13 |
| CureVac–TiberendStrategic Advisors: public relations, 201706 service existent by Tiberend |
2017-06-13 |
| Kaken Pharmaceutical–Numab: therapeutic antibody, 201706– collab + license option €na for multispecific antibody for inflammatory disease |
2017-06-13 |
| 4SC–SEVERAL: investment, 201706–201707 cash capital increase €41m with 11.68m new shares at €3.5/share |
2017-06-12 |
| Teneobio–Selexis: cell line development, 201706– supply service access to SUREtechnology platform to develop cell expression of UniAbs |
2017-06-12 |
| Lilly–Nordic Bioscience: antidiabetic, 201706– strategic collab $55m upfront + milestones + royalties ww rights to develop DACRAs from KeyBioscience |
2017-06-08 |
| Grünenthal–AstraZeneca: zolmitriptan, 201706 acquisition ww rights excl JP to Zomig $200m upfront + $102m milestones by Grünenthal |
2017-06-07 |
| Omeicos–Germany (govt): grant, 201706– additional BMBF research grant €1.7m |
2017-06-07 |
| CRISPR Therapeutics–Orgenesis: CAR-T cell therapies, 201706– supply CDMO services for allogenic CAR-T therapy CTX101 by MaSTherCell SA |
2017-06-06 |
| Thermo Fisher–Biocrates: AbsoluteIDQ Kits, 201706– collab co-marketing of new AbsoluteIDQ p400 HR Kit with Q Exactive HRAM MS systems |
2017-06-05 |
| Thermo Fisher–Biognosys: mass spectrometry s/w, 201706– collab co-marketing of Spectronaut Pulsar s/w with Orbitrap mass spectrometers |
2017-06-05 |
| Univ Maastricht–Bruker: mass spectrometry software, 201706 supply existent use of SCilS Lab s/w by M4I |
2017-06-05 |
| Merck (DE)–F-Star: antibody cancer drug, 201706– strategic collab €115m upfront + €1b milestones develop 5 bispecific ABs incl lead asset FS118 |
2017-06-04 |
| BMS–Qiagen: molecular companion diagnostics, 201706– collab using NGS to develop gene expression profiles for cancer immunotherapies |
2017-06-03 |
| Qiagen–Johns Hopkins Univ: cancer biomarker, 201705– license ww to genetic biomarkers for use in I-O patient selection |
2017-06-03 |
| GATC Biotech–Eurofins: investment, 201706–201707 acquisition €na of GATC Biotech AG by Eurofins Scientific SE |
2017-06-02 |
| Bicycle Therapeutics–SEVERAL: investment, 201706 financing round Series B £40m led by new investor Vertex Ventures HC |
2017-06-01 |
| Indivumed–LADR/Intermed: investment, 201706 investment by Intermed as part of strategic alliance |
2017-06-01 |
| Waters–Andrew Alliance: automated liquid handling technology, 201706– collab co-marketing semi-automated sample prep solution |
2017-06-01 |
| Inthera Bioscience–SEVERAL: investment, 201705 financing round Series A CHF10.5m Merck Ventures + Aglaia BioMedical + Novo Seeds + private investor |
2017-05-31 |
| Strekin–SEVERAL: investment, 201705 financing round Series C CHF10m from private investors |
2017-05-31 |
| High-Tech Gründerfonds–SEVERAL: investment, 201705 first closing €245m of High-Tech Gründerfonds III (HTGF III) |
2017-05-30 |
| Taconic–ERS Genomics: CRISPR technology, 201705– license ww non-excl for CRISPR-Cas9 technology to generate murine models |
2017-05-30 |
| ViraTherapeutics–MC Services: public relations, 201705 service existent by MC Services |
2017-05-30 |
| Wise (IT)–SEVERAL: investment, 201705 financing round Series B €6.5m led by Principia SGR + incl Atlante Ventures + HTGF + F3F + Antares |
2017-05-25 |
| Debiopharm–ImmunoGen: antibody-drug conjugate, 201704 acquisition $25m upfront + $30m milestones of anti-CD37 ADC IMGN529 by Debiopharm |
2017-05-24 |
| Sartorius–SEVERAL: credit, 201705– note loan €350m with maturity terms of 5, 7 + 10 years arranged by Commerzbank + LBBW |
2017-05-24 |
| OSE Immunotherapeutics–Selexis: cell line development, 201705– commercial license for access to RCBs from SUREtechnology platform |
2017-05-23 |
| Signatope–High-Tech Gründerfonds: investment, 201705 investment €600k by HTGF |
2017-05-23 |
| TolerogenixX–High-Tech Gründerfonds: investment, 201705 seed financing from HTGF |
2017-05-23 |
| Clariant–Huntsman: investment, 201705–201710 merger of equals NOT REALISED |
2017-05-21 |
| Boehringer–Anagenesis: drug discovery technology, 201705– excl license to P2MC technology for drug developm for chronic muscle diseases |
2017-05-18 |
| Boehringer–Peking Univ: pharma r+d, 201705– collab strategic alliance incl therapeutics + regenerative medicine + gene therapy |
2017-05-16 |
| Exosomics Siena–Lonza: investment, 201705 strategic investment by Lonza |
2017-05-16 |
| HansaBioMed Life Sciences–Lonza: investment, 201705 acquisition of HBM-LS by Lonza |
2017-05-16 |
| Vesalius Biocapital–SEVERAL: investment, 201705 first closing €65m of Vesalius Biocapital III fund |
2017-05-15 |
| Cardior Pharmaceuticals–SEVERAL: investment, 201705 financing round Series A €15m led by LSP + BIVF + BMS + BioMedPartners + HTGF |
2017-05-11 |
| Numaferm–EU (govt): investment, 201705 seed financing round totalling €7-digit incl European Investment Fund |
2017-05-11 |
| Numaferm–High-Tech Gründerfonds: investment, 201705 seed financing round totalling €7-digit incl HTGF |
2017-05-11 |
| Numaferm–PERSON: investment, 201705 seed financing round totalling €7-digit incl business angels + Qiagen founders Detlev Riesner + Jürgen Schumacher |
2017-05-11 |
| Numaferm–SEVERAL: investment, 201705 seed financing round €7-digit from HTGF + Detlev Riesner + Jürgen Schumacher + EIF |
2017-05-11 |
| BC Platforms–Debiopharm: investment, 201705 financing round Series B totalling $10m co-led by Debiopharm Innovation Fund + Tesi |
2017-05-09 |
| BC Platforms–SEVERAL: investment, 201705 financing round Series B $10m co-led by Debiopharm Innovation Fund + Tesi |
2017-05-09 |
| BC Platforms–Tesi (FI): investment, 201705 financing round Series B totalling $10m co-led by Debiopharm Innovation Fund + Tesi |
2017-05-09 |
| Grzybowski Scientific Inventions–Merck (DE): investment, 201705 acquisition of GSI by Merck |
2017-05-09 |
| Aadi Bioscience–Helsinn: investment, 201705 financing round Series A totalling $23m incl $2m from co-investor Helsinn Investment Fund |
2017-05-08 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 21 22 23 ... 30 31 32 
Date
![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
